Lupin

LUPIN26 Apr 2024

Pharmaceuticals

₹

+21.55 (+1.35%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in Lupin

Lupin

Pharmaceuticals

LUPIN26 Apr 2024

₹

+21.55 (+1.35%)

OverviewFundamentalsFutures Options

Corporate action

Peer comparison

Income Sheet

Balance sheet

Cash flow

Share holding

About Us

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date	Ratio
05-May-2010	S	Lupin Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 05, 2010, inter alia, has approved the following: 1. Approved the sub-division of equity shares of the face value of Rs. 10/- each in the Company into shares with the face value of Rs. 2/- each. The sub-division would be subject to the approval of the shareholders at the ensuing annual general meeting and such other approvals as may be necessary. Lupin Ltd has informed BSE that August 30, 2010 has been fixed as the Record Date for the purpose of sub-division / stock split of Rs. 10/- per share of the Company into the shares of Rs. 2/- each. Lupin Ltd has informed BSE that the members at the 28th Annual General Meeting (AGM) of the Company held on July 28, 2010, inter alia, have passed resolution to sub-divide 100,000,000 Equity Shares of the Company of face value of Rs. 10/- each into 500,000,000 Equity Shares of face value of Rs. 2/- each. (As Per BSE Announcement Website dated on 30.07.2010) SUB. :- Sub Division of equity shares of Lupin Limited (Scrip Code 500257) Trading Members of the Exchange are hereby informed that, Lupin Limited has fixed the Record Date for the purpose of sub division of equity shares of the company. DEMATERIALISED SECURITIES - ROLLING SETTLEMENT SEGMENT COMPANY NAME & CODE Lupin Limited (500257 & 600257) RECORD DATE 30/08/2010 PURPOSE Sub Division of existing equity shares from every ONE equity share of Rs.10/- each into FIVE equity shares of Rs.2/- each. SUB-DIVIDED PAID-UP VALUE Rs.2/- SUB-DIVIDED PAID-UP VALUE W.E.F. 27/08/2010 DR- 107/2010- 2011 Note:- i. Trading members are hereby informed that the transactions in the equity shares (physical) of the aforesaid company in the Exit-Route Scheme will be for Rs. 2/- paid up w.e.f. 27/08/2010. ii. ISIN No. INE 326 A01029 of Rs.10/- paid up will not be valid for transactions done on the Exchange on or after 27/08/2010. iii. The new ISIN Number for Rs.2/- paid up will be informed to the market by a separate notice. (As Per BSE Notice Dated on 02.08.2010)	30-Aug-2010
09-May-2023	D	Audited Financial Statements for the quarter and year ended March 31, 2023. Regulation 30(2) read with Schedule Ill Part A Para A (4) (a) of the Listing Regulations, recommended dividend @ 2003 i.e. 4/- per equity share of the face value of 2 each for the year ended March 31, 2023, subject to approval of Members at the ensuing Annual General Meeting. The total outflow would be 1820.1 million The Company has fixed Friday, July 14, 2023, as the ''Record Date'' for the purpose of ascertaining the shareholders who will be entitled to payment of Dividend. (As Per BSE Announcement dated on 04.07.2023)	14-Jul-2023
19-May-2022	D	Lupin Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 18, 2022, inter alia, has recommended dividend @200% i.e.Rs. 4/- per equity share of the face value of Rs. 2/- each for the year ended March 31, 2022, subject to approval of Members at the ensuing Annual General Meeting. The total outflow would be Rs. 1818 million.	14-Jul-2022
13-May-2021	D	Lupin Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 12, 2021, inter alia, has recommended dividend @ 325% i.e. Rs. 6.50 per equity share of the face value of Rs. 2/- each for the year ended March 31, 2021, subject to approval of Members at the ensuing Annual General Meeting. The total outflow would be Rs. 2949.2 mn.	27-Jul-2021
29-May-2020	D	Lupin Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 28, 2020, inter alia, has recommended dividend @ 300% i.e. Rs. 6/- per equity share of the face value of Rs. 2/- each for the year ended March 31, 2020, subject to approval of Members at the ensuing Annual General Meeting. The total outflow will be Rs. 2718.4 mn.	03-Aug-2020
15-May-2019	D	Lupin Ltd has informed BSE that the Board of Directors of the Company at its Meeting held on May 15, 2019, inter alia, has recommended dividend @ 250% i.e. Rs. 5/- per equity share of the face value of Rs. 2/- each for the year ended March 31, 2019, subject to approval of Members at the ensuing Annual General Meeting.	29-Jul-2019
15-May-2018	D	Lupin Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 15, 2018, inter alia, recommended dividend @ 250% i.e. Rs. 5/- per equity share of the face value of Rs. 2/- each for the year ended March 31, 2018, subject to approval of the Members at the ensuing Annual General Meeting.	30-Jul-2018
24-May-2017	D	Lupin Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 24, 2017, inter alia, has recommended dividend @ 375% i.e. Rs. 7.50 per equity share of the face value of Rs. 2/- each for the year ended March 31, 2017, subject to approval of the Members at the ensuing Annual General Meeting.	24-Jul-2017
19-May-2016	D	Lupin Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 19, 2016, inter alia, recommended dividend @ 375% i.e. Rs. 7.50 per equity share of the face value of Rs. 2/- each for the year ended March 31, 2016, subject to approval of the members at the ensuing Annual General Meeting. The Board Meeting commenced at 11.00 a.m. and concluded at 1.45 p.m.	25-Jul-2016
13-May-2015	D	Lupin Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 13, 2015, inter alia, has recommended dividend @ 375% i.e. Rs. 7.50 per equity share of the face value of Rs. 2/- each for the year ended March 31, 2015, subject to approval of the members at the ensuing Annual General Meeting.	14-Jul-2015
03-May-2014	D	Lupin Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 07, 2014, inter alia, has recommended final dividend @ 150% i.e. Rs. 3/- per equity share of the face value of Rs. 2/- each for the year ended March 31, 2014 subject to the approval of the shareholders at the ensuing Annual General Meeting. The Board of Directors had at their meeting held on February 03, 2014, declared and paid interim dividend of Rs. 3/- per equity share of Rs. 2/- each. Thus, the total dividend for the year ended March 31, 2014 would be Rs. 6/- per equity share.	21-Jul-2014
03-Feb-2014	D	Lupin Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 03, 2014, inter alia, has declared an interim dividend @ 150% i.e. Rs. 3/- per fully paid-up equity share of Rs. 2/- each absorbing a sum of Rs. 1345 million for the year ending March 31, 2014.	13-Feb-2014
08-May-2013	D	Lupin Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 08, 2013, inter alia, has recommended dividend @ 200% i.e. Rs. 4/- per equity shares of the face value of Rs. 2/- each for the year ended March 31, 2013.	29-Jul-2013
10-May-2012	D	Lupin Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 10, 2012, inter alia, has recommended dividend @ 160% i.e. Rs. 3.20 per equity share of the face value of Rs. 2/- each for the year ended March 31, 2012.	13-Jul-2012
12-May-2011	D	Lupin Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 12, 2011, inter alia, has recommended dividend @ 150% i.e. Rs. 3/- per equity share of the face value of Rs. 2/- each for the year ended March 31, 2011.	18-Jul-2011
05-May-2010	D	Lupin Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 05, 2010, inter alia, has approved the following: Recommended dividend @ 135% i.e. Rs. 13.50 per equity share of the face value of Rs. 10/- each for the year ended March 31, 2010.	19-Jul-2010
13-May-2009	D	Lupin Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 13, 2009, inter alia, has recommended dividend @ 125% i.e. Rs 12.50 per equity share of the face value of Rs 10/- each for the year ended March 31, 2009.	20-Jul-2009
14-May-2008	D	Lupin Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 14, 2008, inter alia, has recommended dividend @ 100% i.e. Rs 10/- per equity share of the face value of Rs 10/- each (including a special dividend @ 50% i.e. Rs 5/- per equity share) for the year ended March 31, 2008.	11-Jul-2008
14-May-2008	D	Lupin Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 14, 2008, inter alia, has recommended dividend @ 100% i.e. Rs 10/- per equity share of the face value of Rs 10/- each (including a special dividend @ 50% i.e. Rs 5/- per equity share) for the year ended March 31, 2008.	11-Jul-2008
09-May-2007	D	Lupin Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 09, 2007, inter alia, has recommended dividend @ 50% i.e. Rs 5/- per equity share of the face value of Rs 10/- each, for the year ended March 31, 2007.	10-Jul-2007
05-Aug-2005	D	65% Dividend	15-Jul-2005
03-Aug-2006	B	Trading Members of the Exchange are hereby informed that, Lupin Ltd. has fixed the Record Date for the purpose of Bonus Issue. The transactions in the equity shares of the company should be on an ex-bonus basis with effect from the under mentioned date. DEMATERIALISED SECURITIES - ROLLING SETTLEMENT SEGMENT COMPANY NAME CODE Lupin Ltd. 500257 & 600257 RECORD DATE 14/08/2006 PURPOSE ONE fully paid-up Bonus equity share for every ONE existing equity share held. TRANSACTIONS IN EQUITY SHARES ON Cum-Bonus basis up to Date & Sett. No. 10/08/2006 DR-095/2006-2007 Ex-Bonus basis from Date & Sett. No. 11/08/2006 DR-096/2006-2007 Trading Members of the Exchange are requested to take note of it.	14-Aug-2006	1:1
22-Apr-2024	BC	LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/05/2024 ,inter alia, to consider and approve audited financial results of the Company for the q	06-May-2024
22-Apr-2024	BC	Trading Members of the Exchange are hereby informed that the further new securities issued by the under mentioned companies are listed and admitted for trading on the Exchange with effect from Tuesda	23-Apr-2024
05-Apr-2024	BC	Trading Members of the Exchange are hereby informed that the further new securities issued by the under mentioned companies are listed and admitted for trading on the Exchange with effect from Monday	08-Apr-2024
27-Mar-2024	BC	Trading Members of the Exchange are hereby informed that the further new securities issued by the under mentioned companies are listed and admitted for trading on the Exchange with effect from Thursd	28-Mar-2024
22-Mar-2024	BC	The Company plans to carve out, its trade generics business in India, as a going concern, on a slump sale basis, to Lupin Life Sciences Limited, wholly owned subsidiary of the Company.	22-Mar-2024

Announcement Date09-May-2023

Ex Dividend Date14-Jul-2023

Dividend(%)200

Announcement Date19-May-2022

Ex Dividend Date14-Jul-2022

Dividend(%)200

Announcement Date13-May-2021

Ex Dividend Date27-Jul-2021

Dividend(%)325

Announcement Date29-May-2020

Ex Dividend Date03-Aug-2020

Dividend(%)300

Announcement Date15-May-2019

Ex Dividend Date29-Jul-2019

Dividend(%)250

Announcement Date15-May-2018

Ex Dividend Date30-Jul-2018

Dividend(%)250

Announcement Date24-May-2017

Ex Dividend Date24-Jul-2017

Dividend(%)375

Announcement Date19-May-2016

Ex Dividend Date25-Jul-2016

Dividend(%)375

Announcement Date13-May-2015

Ex Dividend Date14-Jul-2015

Dividend(%)375

Announcement Date03-May-2014

Ex Dividend Date21-Jul-2014

Dividend(%)150

Announcement Date03-Feb-2014

Ex Dividend Date13-Feb-2014

Dividend(%)150

Announcement Date08-May-2013

Ex Dividend Date29-Jul-2013

Dividend(%)200

Announcement Date10-May-2012

Ex Dividend Date13-Jul-2012

Dividend(%)160

Announcement Date12-May-2011

Ex Dividend Date18-Jul-2011

Dividend(%)150

Announcement Date05-May-2010

Ex Dividend Date19-Jul-2010

Dividend(%)135

Announcement Date13-May-2009

Ex Dividend Date20-Jul-2009

Dividend(%)125

Announcement Date14-May-2008

Ex Dividend Date11-Jul-2008

Dividend(%)50

Announcement Date14-May-2008

Ex Dividend Date11-Jul-2008

Dividend(%)50

Announcement Date09-May-2007

Ex Dividend Date10-Jul-2007

Dividend(%)50

Announcement Date05-Aug-2005

Ex Dividend Date15-Jul-2005

Dividend(%)65

No Rights has been declared by LUPIN

Book Closure

Record Date	Split Date	Purpose
06-May-2024	-	LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/05/2024 ,inter alia, to consider and approve audited financial results of the Company for the q
23-Apr-2024	-	Trading Members of the Exchange are hereby informed that the further new securities issued by the under mentioned companies are listed and admitted for trading on the Exchange with effect from Tuesda
08-Apr-2024	-	Trading Members of the Exchange are hereby informed that the further new securities issued by the under mentioned companies are listed and admitted for trading on the Exchange with effect from Monday
28-Mar-2024	-	Trading Members of the Exchange are hereby informed that the further new securities issued by the under mentioned companies are listed and admitted for trading on the Exchange with effect from Thursd
22-Mar-2024	-	The Company plans to carve out, its trade generics business in India, as a going concern, on a slump sale basis, to Lupin Life Sciences Limited, wholly owned subsidiary of the Company.

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Lupin Ltd ₹1,615.95(+21.55/1.35%)	1,615.95	+21.55	73,646.94	128.34	35.73	3.82
Ipca Laboratories Ltd ₹1,338.50(+10.05/0.76%)	1,338.50	+10.05	33,958.31	90.83	61.69	5.47
J B Chemicals & Pharmaceuticals Ltd ₹1,865.05(+2.25/0.12%)	1,865.05	+2.25	28,944.61	77.48	57.14	10.78
Brooks Laboratories Ltd ₹108.95(+2.10/1.97%)	108.95	+2.10	285.96	72.14	0.00	4.16
Sanofi India Ltd ₹8,274.15(+120.75/1.48%)	8,274.15	+120.75	19,055.37	38.57	32.28	18.77
IOL Chemicals & Pharmaceuticals Ltd ₹399.50(-0.85/-0.21%)	399.50	-0.85	2,345.28	-2.77	13.60	1.48

Income Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	3999.47	3560.23	3425.01	2744.56	2835.44	2778.88
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	3999.47	3560.23	3425.01	2744.56	2835.44	2778.88
Other Operating Income	116.28	99.00	70.63	91.71	25.67	50.08
Other Income	23.16	25.60	27.74	55.30	17.10	15.37
Total Income	4138.91	3684.83	3523.38	2891.57	2878.21	2844.33
Total Expenditure	2898.41	2823.99	2790.62	2574.09	2645.98	2515.30
PBIDT	1240.50	860.84	732.76	317.48	232.23	329.03
Interest	11.36	15.32	16.18	29.44	30.75	18.38
PBDT	1229.14	845.52	716.58	288.04	201.48	310.65
Depreciation	145.18	149.48	140.05	146.20	134.03	137.76
Tax	184.61	129.66	100.72	25.42	12.76	28.77
Deferred Tax	-17.09	17.77	-1.15	-2.59	14.29	-4.50
Reported Profit After Tax	916.44	548.61	476.96	119.01	40.40	148.62
Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	916.44	548.61	476.96	119.01	40.40	148.62

EPS (Unit Curr.)	20.14	12.06	10.48	2.62	0.89	3.27
EPS (Adj) (Unit Curr.)	20.14	12.06	10.48	2.62	0.89	3.27
Calculated EPS (Unit Curr.)	20.13	12.05	10.48	2.62	0.89	3.27
Calculated EPS (Adj) (Unit Curr.)	20.13	12.05	10.48	2.62	0.89	3.27
Calculated EPS (Ann.) (Unit Curr.)	80.50	48.20	41.92	10.46	3.55	13.07
Calculated EPS (Adj) (Ann.) (Unit Curr.)	80.50	48.20	41.92	10.46	3.55	13.07
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	91.07	91.05	91.02	91.00	90.96	90.94
Reserve & Surplus	0.00	0.00	0.00	0.00	0.00	0.00
Face Value	2.00	2.00	2.00	2.00	2.00	2.00

Public Shareholding (No. Of Shares)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (% in Equity)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	31.02	24.18	21.39	11.57	8.19	11.84
PBDTM(%)	30.73	23.75	20.92	10.49	7.11	11.18
PATM(%)	22.91	15.41	13.93	4.34	1.42	5.35

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	5079.88	4939.23	4742.12	4330.30	4244.56	4091.16
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	5079.88	4939.23	4742.12	4330.30	4244.56	4091.16
Other Operating Income	117.53	99.33	71.94	99.78	77.66	54.36
Other Income	29.37	40.40	22.83	37.27	17.96	14.94
Total Income	5226.78	5078.96	4836.89	4467.35	4340.18	4160.46
Total Expenditure	4159.47	4120.80	3957.77	3852.31	3789.55	3692.53
PBIDT	1067.31	958.16	879.12	615.04	550.63	467.93
Interest	74.01	80.64	85.67	92.55	84.09	54.88
PBDT	993.30	877.52	793.45	522.49	466.54	413.05
Depreciation	257.20	247.85	234.66	263.99	220.40	203.47
Minority Interest Before NP	0.00	0.00	0.00	0.00	0.00	0.00
Tax	225.51	172.31	129.99	29.65	58.74	80.34
Deferred Tax	-108.11	-37.96	-24.53	-13.54	29.75	-5.23
Reported Profit After Tax	618.70	495.32	453.33	242.39	157.65	134.47
Minority Interest After NP	5.58	5.65	1.07	6.43	4.18	4.74
Net Profit after Minority Interest	613.12	489.67	452.26	235.96	153.47	129.73

Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	613.12	489.67	452.26	235.96	153.47	129.73

EPS (Unit Curr.)	13.47	10.76	9.94	5.19	3.38	2.85
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	91.07	91.05	91.00	91.00	90.96	90.94

Public Shareholding (Number)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (%)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	21.01	19.40	18.54	14.20	12.97	11.44
PBDTM(%)	19.55	17.77	16.73	12.07	10.99	10.10
PATM(%)	12.18	10.03	9.56	5.60	3.71	3.29

Balance Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	91.00	90.90	90.74	90.60	90.50	90.42
Reserves Total	18320.86	18059.29	18474.78	17382.52	17026.77	15694.54
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.05	0.08	0.00	0.00
Total Shareholders Funds	18411.86	18150.19	18565.57	17473.20	17117.27	15784.96
Secured Loans	0.00	0.00	50.79	5.29	1.68	8.21
Unsecured Loans	748.51	950.85	434.67	0.54	4.08	8.89
Total Debt	748.51	950.85	485.46	5.83	5.76	17.10
Total Liabilities	19160.37	19101.04	19051.03	17479.03	17123.03	15802.06
APPLICATION OF FUNDS :
Gross Block	7408.43	6705.14	6230.28	5666.14	4807.56	4373.05
Less : Accumulated Depreciation	3386.50	3014.96	2591.45	2152.26	1434.61	1032.39
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	4021.93	3690.18	3638.83	3513.88	3372.95	3340.66
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	926.59	947.44	950.86	822.00	1199.09	1171.04
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	9974.33	9511.09	9562.58	7456.43	7388.47	5362.85
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	3019.47	3177.14	2708.19	2484.61	2305.98	2180.02
Sundry Debtors	2674.42	2722.01	3190.54	3616.33	3724.32	4946.31
Cash and Bank	100.97	64.56	284.01	1305.93	61.44	110.96
Loans and Advances	1336.29	1651.71	1113.64	1101.91	1285.39	1247.57
Total Current Assets	7131.15	7615.42	7296.38	8508.78	7377.13	8484.86
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	2132.40	1887.09	1693.38	1960.10	1495.17	2149.38
Provisions	812.04	800.25	539.17	590.17	496.99	173.81
Total Current Liabilities	2944.44	2687.34	2232.55	2550.27	1992.16	2323.19
Net Current Assets	4186.71	4928.08	5063.83	5958.51	5384.97	6161.67
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	0.00	0.00	0.00	162.06	140.72	146.95
Deferred Tax Liability	185.02	186.75	217.32	355.00	406.94	405.28
Net Deferred Tax	-185.02	-186.75	-217.32	-192.94	-266.22	-258.33
Total Assets	18924.54	18890.04	18998.78	17557.88	17079.26	15777.89
Contingent Liabilities	3762.43	3472.56	4875.59	6559.75	8436.04	6861.76

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	91.00	90.90	90.74	90.60	90.50	90.42
Reserves Total	12373.50	12062.37	13712.35	12446.02	13651.73	13486.64
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.05	0.08	0.00	0.00
Total Shareholders Funds	12464.50	12153.27	13803.14	12536.70	13742.23	13577.06
Minority Interest	78.32	68.71	54.97	44.46	46.86	40.08
Secured Loans	0.00	141.86	242.92	175.61	446.18	6930.61
Unsecured Loans	4541.52	4016.52	4886.16	6129.71	8049.89	212.19
Total Debt	4541.52	4158.38	5129.08	6305.32	8496.07	7142.80
Policy Holders Fund	0.00	0.00	0.00	0.00	0.00	0.00
Other Liabilities	704.41	718.15	811.66	1184.67	1100.41	882.66
Total Liabilities	17788.75	17098.51	19798.85	20071.15	23385.57	21642.60
APPLICATION OF FUNDS :
Gross Block	18077.42	15990.30	14726.75	14160.50	15731.88	13859.86
Less: Accumulated Depreciation	9722.18	8608.68	6845.99	6222.39	4645.17	3497.87
Less: Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	8355.24	7381.62	7880.76	7938.11	11086.71	10361.99
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	1237.99	1146.28	1066.26	939.62	1639.71	2598.20
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	516.90	900.00	2454.88	2374.32	2295.49	261.57
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	4491.76	4630.73	4092.01	3456.87	3836.77	3662.49
Sundry Debtors	4480.70	4261.94	4474.32	5445.93	5149.80	5192.21
Cash and Bank	1293.13	1098.13	1742.46	2454.30	987.20	1408.03
Loans and Advances	1745.94	1644.48	1300.77	1717.86	1769.95	1711.95
Total Current Assets	12011.53	11635.28	11609.56	13074.96	11743.72	11974.68
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	3997.67	3584.76	2976.28	3517.24	3503.86	3826.02
Provisions	940.08	897.12	605.54	1195.92	771.66	551.23
Total Current Liabilities	4937.75	4481.88	3581.82	4713.16	4275.52	4377.25
Net Current Assets	7073.78	7153.40	8027.74	8361.80	7468.20	7597.43
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	155.65	169.73	180.21	174.31	734.00	716.56
Deferred Tax Liability	229.43	240.83	229.77	199.54	288.28	285.53
Net Deferred Tax	-73.78	-71.10	-49.56	-25.23	445.72	431.03
Other Assets	678.62	588.31	418.77	482.53	449.74	392.38
Total Assets
Contingent Liabilities	393.72	371.71	419.62	325.39	795.95	652.54

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019
Cash and Cash Equivalents at Beginning of the year	59.10	177.41	1168.02	55.94	105.67
Net Cash from Operating Activities	1793.99	151.03	1570.08	2219.49	3110.72
Net Cash Used In Investing Activities	-1269.17	-371.79	-2507.52	-739.56	-2865.07
Net Cash Used In Financing Activities	-498.26	102.45	-53.17	-367.85	-295.38
Net Inc./Dec In Cash And Cash Equivalents	26.56	-118.31	-990.61	1112.08	-49.73
Cash And Cash Equivalents At End Of The Year	85.66	59.10	177.41	1168.02	55.94

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

47.01%

FII Shareholding

18.28%

DII Shareholding

27.77%

Public Shareholding

6.93%

**Promoter pledged shareholding 47.01%

About Lupin Ltd

Lupin Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 73642.38 crores. It has reported a sales of Rs. 3999.47 crores and a net profit of Rs. 916.44 crores for the quarter ended December 2018. The company management includes M D Gupta, M D Gupta,Nilesh Deshbandhu Gupta.,Vinita Gupta,R V Satam,Jean-Luc Belingard,Ramesh Swaminathan,Mark D McDade,K B S Anand,Punita Kumar Sinha (Lupin Ltd) among others.

Chairman

M D Gupta

Registered office

Kalpataru Inspire 3rd Floor,Off Western Exp HW Santacruz-E,Mumbai,Maharashtra,400055

FAX :91-22-6640 8131

Background

Incorporation Year1983

Face Value₹2

Market Lot1

How to buy Lupin shares on nse?

To buy Lupin shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Lupin share price today?

The Lupin shares price on nse is Rs.1615.95 today.

What is the market cap of Lupin shares on NSE ?

The company has a market capitalization of Rs.73646.94Cr

What is the PE & PB ratio of Lupin shares ?

PE is 35.73 and PB is 3.82

What is the 52 Week High and Low of Lupin shares?

Lupin stock price high: Rs.1704.25 Lupin stock price low: Rs.680

What can be the price of Lupin stocks on BSE?

As of 13:15 hours on 12th May 2023, the stock price of Lupin on the BSE was rupees 773. The price fluctuates constantly throughout trading hours. So, check for the updated price when you invest.

Is it safe to buy Lupin stocks?

Lupin is a leading name in the pharmaceutical sector. It has a market capitalization of rupees 34,804.93 crores with an average trading volume of 61,434.45. The stock might suffer price fluctuations in the short-run depending on market movements. However, the stock price might appreciate and give good returns over the long term. So, it is safe to invest in Lupin if you have a long-term horizon.

What is the current market value per stock of Lupin stocks?

As of 13:15 hours on 12th May 2023, the current market value is rupees 773 on the BSE and rupees 773.10 on the NSE.

Does Lupin have any debts?

Yes, Lupin has debt in its balance sheet. As of 31st March 2023, Lupin had secured loans worth rupees 613.46 crores.

Will Lupin's stock price increase?

While Lupin is trading at rupees 773 on 12th May 2023, its lower circuit is quoted at rupees 688.45, and the upper circuit is at rupees 841.35. Considering the upper circuit, the company’s stock price is expected to increase. Moreover, if you stay invested over a long-term horizon, you can witness a gain in the stock price as the short-term volatilities smoothen out and the company grows.

What is the business plan of Lupin?

Lupin aims to expand its domestic and international business with increased manufacturing of its popular drugs. The company specifically targeted growth in the US and China which would boost its revenue and profitability.